Surgically treated ovarian endometriosis association with BRCA1 and BRCA2 mutations

被引:8
|
作者
Aviel-Ronen, Sarit [1 ,2 ]
Soriano, David [3 ,4 ]
Shmuel, Elyasaf [3 ]
Schonman, Ron [3 ]
Rosenblatt, Kinneret [1 ]
Zadok, Oranit [1 ]
Vituri, Aya [5 ]
Seidman, Daniel [3 ]
Barshack, Iris [1 ,4 ]
Cohen, Yoram [3 ,4 ]
机构
[1] Chaim Sheba Med Ctr, Dept Pathol, IL-52621 Tel Hashomer, Israel
[2] Chaim Sheba Med Ctr, Talpiot Med Leadership Program, IL-52621 Tel Hashomer, Israel
[3] Chaim Sheba Med Ctr, Dept Obstet & Gynecol, IL-52621 Tel Hashomer, Israel
[4] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel
[5] Tel Aviv Univ, Dept Stat & Operat Res, IL-69978 Tel Aviv, Israel
基金
以色列科学基金会;
关键词
Endometriosis; Ovarian cancer; BRCA1; BRCA2; MALDI-TOF-MS; BREAST-CANCER; GENE POLYMORPHISMS; CARRIER FREQUENCY; RISK; WOMEN; CARCINOMA; GSTM1; HETEROZYGOSITY; SUSCEPTIBILITY; TRANSFERASE;
D O I
10.1016/j.prp.2013.12.011
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Endometriosis is associated with an increased risk of ovarian cancer. Few studies have also shown increased risk of breast cancer. BRCA1/2 mutations are linked to an increased risk of breast and ovarian cancers but their relation to endometriosis is unknown. The objective of this study was to examine the mutation rate of BRCA1/2 among women with surgically treated ovarian endometriosis. We collected 126 specimens from Jewish Ashkenazi women with endometriotic (76) and control non-endometriotic (50) ovarian cysts, reviewed the pathological diagnoses and extracted DNA from all samples. Using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), samples were examined for the founder germline mutations of BRCA1/2, most common among Ashkenazi Jews. The rate of mutations in each group was calculated and compared. BRCA1/2 mutation rate was 1/76(1.3%) in the endometriotic cyst study group and 1/50(2%) in the control non-endometriotic cysts, showing no statistically significant difference between the groups (p = 0.84). BRCA1/2 mutation rate was similar to the previously reported rate among Jewish Ashkenazi women. BRCA1/2 mutation rates in patients with endometriotic ovarian cysts and with non-endometriotic ovarian cysts are similar. A larger cohort is required to completely exclude the possibility of an association between BRCA1/2 mutations and surgically treated endometriosis. (C) 2014 Elsevier GmbH. All rights reserved.
引用
下载
收藏
页码:250 / 255
页数:6
相关论文
共 50 条
  • [31] BRCA1 and BRCA2 alterations in ovarian MMMT
    Geisler, JP
    Goodheart, MJ
    Buller, RE
    GYNECOLOGIC ONCOLOGY, 2004, 95 (03) : 774 - 774
  • [32] BRCA1 and BRCA2 mutations and female fertility
    Smith, Ken R.
    Hanson, Heidi A.
    Hollingshaus, Michael S.
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2013, 25 (03) : 207 - 213
  • [33] Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma
    Majdak, EJ
    Debniak, J
    Milczek, T
    Cornelisse, CJ
    Devilee, P
    Emerich, J
    Jassem, J
    De Bock, GH
    CANCER, 2005, 104 (05) : 1004 - 1012
  • [34] High Frequency of BRCA1 and BRCA2 Germline Mutations in a Series of Resected Pancreatic Adenocarcinoma and Other Preneoplastic Lesions Suggests an Association With BRCA1 and BRCA2 Mutations
    Lucas, Aimee L.
    Mitchel, Elana B.
    Hwang, Caroline
    Kumar, Sheila
    Deng, Liyong
    Shakya, Reena
    Ludwig, Thomas
    Chabot, John A.
    Chung, Wendy
    Frucht, Hatold
    GASTROENTEROLOGY, 2011, 140 (05) : S355 - S355
  • [35] Are Endometrial Cancers Arising in BRCA1/BRCA2 Germline Mutations Carriers True BRCA1/BRCA2 Cancers?
    Paula, Arnaud Da Cruz
    Smith, Evan
    Cadoo, Karen
    Abu-Rustum, Nadeem
    Pei, Xin
    Riaz, Nadeem
    Robson, Mark
    Reis-Filho, Jorge
    Mandelker, Diana
    Weigelt, Britta
    MODERN PATHOLOGY, 2019, 32
  • [36] Are Endometrial Cancers Arising in BRCA1/BRCA2 Germline Mutations Carriers True BRCA1/BRCA2 Cancers?
    Paula, Arnaud Da Cruz
    Smith, Evan
    Cadoo, Karen
    Abu-Rustum, Nadeem
    Pei, Xin
    Riaz, Nadeem
    Robson, Mark
    Reis-Filho, Jorge
    Mandelker, Diana
    Weigelt, Britta
    LABORATORY INVESTIGATION, 2019, 99
  • [37] BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and ovarian cancer
    Schubert, EL
    Mefford, HC
    Dann, JL
    Argonza, RH
    Hull, J
    King, MC
    GENETIC TESTING, 1997, 1 (01): : 41 - 46
  • [38] BRCA1 and BRCA2 mutations in ovarian cancer patients from Belarus: update
    Savanevich, Alena
    Ashuryk, Olgierd
    Cybulski, Cezary
    Lubinski, Jan
    Gronwald, Jacek
    HEREDITARY CANCER IN CLINICAL PRACTICE, 2021, 19 (01)
  • [39] Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations
    Satagopan, JM
    Boyd, J
    Kauff, ND
    Robson, M
    Scheuer, L
    Narod, S
    Offit, K
    CLINICAL CANCER RESEARCH, 2002, 8 (12) : 3776 - 3781
  • [40] BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases
    Pal, T
    Permuth-Wey, J
    Betts, JA
    Krischer, JP
    Fiorica, J
    Arango, H
    LaPolla, J
    Hoffman, M
    Martino, MA
    Wakeley, K
    Wilbanks, G
    Nicosia, S
    Cantor, A
    Sutphen, R
    CANCER, 2005, 104 (12) : 2807 - 2816